Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2009
Here are the related meetings in 2021:
Next Generation HIV Vaccines & Therapies - RESCHEDULING IN PROGRESS (B4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Prevention of HIV/AIDS (X3)
Organizer(s) Brigitte Autran and Scott M. Hammer
March 22—27, 2009
Keystone Resort • Keystone, CO USA
Abstract Deadline: Nov 24, 2008
Late Abstract Deadline: Dec 22, 2008
Scholarship Deadline: Nov 24, 2008
Early Registration Deadline: Jan 22, 2009
Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
Joint Meeting:
HIV Immunobiology: From Infection to Immune Control (X4)
Summary of Meeting:
Most recent research efforts on the prevention of HIV and AIDS has focused on T cell-based vaccines but it is admitted this approach will not prevent HIV and needs to be strengthened by novel approaches to generate HIV neutralizing antibodies. The recent successes or failures of alternative methods of HIV prevention (e.g., microbicides, circumcision), or of AIDS prevention (therapeutic vaccines) should help better understand how HIV vaccines can be used, and require sharing basic understanding and results with the prophylactic vaccine field. However the recent negative results of a major HIV vaccine trial have substantially disorganized the field. The goals of the meeting are therefore to focus on the most recent key advances in the understanding of (1) how HIV can be controlled at entry and after infection in 3 joint sessions with the concurrent “HIV Immunobiology” meeting, (2) how T cell-based or antibody-based HIV vaccines can be improved, and (3) what are the results of the current vaccine trials and those of alternative methods of HIV or AIDS prevention and how can they help at re-orientating vaccine researches. Two workshops will provide key information on the definition of immune correlates of protection and their analysis in clinical trials.
View Scholarships/Awards
Most recent research efforts on the prevention of HIV and AIDS has focused on T cell-based vaccines but it is admitted this approach will not prevent HIV and needs to be strengthened by novel approaches to generate HIV neutralizing antibodies. The recent successes or failures of alternative methods of HIV prevention (e.g., microbicides, circumcision), or of AIDS prevention (therapeutic vaccines) should help better understand how HIV vaccines can be used, and require sharing basic understanding and results with the prophylactic vaccine field. However the recent negative results of a major HIV vaccine trial have substantially disorganized the field. The goals of the meeting are therefore to focus on the most recent key advances in the understanding of (1) how HIV can be controlled at entry and after infection in 3 joint sessions with the concurrent “HIV Immunobiology” meeting, (2) how T cell-based or antibody-based HIV vaccines can be improved, and (3) what are the results of the current vaccine trials and those of alternative methods of HIV or AIDS prevention and how can they help at re-orientating vaccine researches. Two workshops will provide key information on the definition of immune correlates of protection and their analysis in clinical trials.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MARCH 22
MONDAY, MARCH 23
TUESDAY, MARCH 24
WEDNESDAY, MARCH 25
THURSDAY, MARCH 26
FRIDAY, MARCH 27
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, MARCH 22
19:30—21:30
Keynote Address (Joint)
*
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC, France
*
Didier Trono,
Ecole Polytechnique Fédérale de Lausanne, Switzerland
Françoise Barré-Sinoussi,
Institut Pasteur, France
HIV Diversity and Pathogenesis
HIV Diversity and Pathogenesis
Rafi Ahmed,
Emory University School of Medicine, USA
Vaccination and Immune Memory
Vaccination and Immune Memory
08:00—11:00
Host Genomics and HIV Disease (Joint)
*
Didier Trono,
Ecole Polytechnique Fédérale de Lausanne, Switzerland
Amalio Telenti,
Centre Hospitalier Universitaire Vaudois, Switzerland
Evolutionary and Integrative Genomics of Susceptibility to HIV
Evolutionary and Integrative Genomics of Susceptibility to HIV
Mary Carrington,
NCI, National Institutes of Health, USA
Immunogenetic Variation Characterizing Exceptional Control of HIV
Immunogenetic Variation Characterizing Exceptional Control of HIV
Bruce D. Walker,
Ragon Institute of MGH, MIT and Harvard, USA
HIV Controllers: A Model for T Cell Vaccination?
HIV Controllers: A Model for T Cell Vaccination?
Ioannis Theodorou,
INSERM U543, France
Short Talk: Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study
Short Talk: Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study
David I. Watkins,
University of Miami, USA
Vaccine-Induced Cellular Responses Control Acute SIV Replication after Heterologous Challenge
Vaccine-Induced Cellular Responses Control Acute SIV Replication after Heterologous Challenge
11:00—12:30
Hands On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
17:00—19:15
The Bigger Picture: Microbicides, Circumcision and Drugs for Prevention
*
Glenda E. Gray,
South African Medical Research Council, South Africa
Bertran Auvert,
CHU Ambroise Paré, France
Circumcision: Uptake and Impact
Circumcision: Uptake and Impact
Minh H. Dinh,
Northwestern University Feinberg School of Medicine, USA
Short Talk: HIV-1 Interactions with Adult Human Penile Epithelium
Short Talk: HIV-1 Interactions with Adult Human Penile Epithelium
Barbara L. Shacklett,
University of California, Davis, USA
Short Talk: Do Mucosal T Cell Responses to HIV-1 Matter?
Short Talk: Do Mucosal T Cell Responses to HIV-1 Matter?
Carolina Herrera,
Imperial College, UK
Short Talk: Early Colorectal Responses to HIV-1 and Modulation by Microbicides
Short Talk: Early Colorectal Responses to HIV-1 and Modulation by Microbicides
Gilda Tachedjian,
Burnet Institute, Australia
Short Talk: Enhancement of HIV-1 Infection is Not Intrinsic to Polyanion-Based Microbicides
Short Talk: Enhancement of HIV-1 Infection is Not Intrinsic to Polyanion-Based Microbicides
Myron S. Cohen,
University of North Carolina at Chapel Hill, USA
Antiretroviral Therapy to Prevent Sexual Transmission of HIV-1
Antiretroviral Therapy to Prevent Sexual Transmission of HIV-1
17:00—19:00
Hiding from Immunity: Reservoirs and Latency
Robert F. Siliciano,
Johns Hopkins University School of Medicine, USA
Quantitative Analysis of the Control of HIV Replication by Drugs and Vaccines
Quantitative Analysis of the Control of HIV Replication by Drugs and Vaccines
Joel N. Blankson,
Johns Hopkins School of Medicine, USA
HIV-1 Latency and Low Level Viremia in Elite Suppressors
HIV-1 Latency and Low Level Viremia in Elite Suppressors
Dana H. Gabuzda,
Dana Farber Cancer Institute, USA
Macrophage Reservoirs
Macrophage Reservoirs
Matthias Geyer,
Max Planck Institute for Molecular Physiology, Germany
Short Talk: Structural Insights into the Cyclin T1–Tat–TAR RNA Transcription Activation Complex
Short Talk: Structural Insights into the Cyclin T1–Tat–TAR RNA Transcription Activation Complex
08:00—11:00
Immune Control of HIV and Virus Escape (Joint)
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois, Switzerland
Immune Correlates of Protection to HIV
Immune Correlates of Protection to HIV
Joseph (Mike) McCune,
Bill & Melinda Gates Foundation, USA
Short Talk: Immune Control in Pathogenic and Nonpathogenic SIV Infection
Short Talk: Immune Control in Pathogenic and Nonpathogenic SIV Infection
Mark Connors,
NIAID, National Institutes of Health, USA
Short Talk: Effective Control of HIV by CD8+ T-Cells is Associated with Infected CD4+ T Cell Elimination: Ramifications for T Cell Based Vaccines
Short Talk: Effective Control of HIV by CD8+ T-Cells is Associated with Infected CD4+ T Cell Elimination: Ramifications for T Cell Based Vaccines
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
Short Talk: Stimulus Package: NIH and the ARRA
Short Talk: Stimulus Package: NIH and the ARRA
Philip J. Goulder,
University of Oxford, UK
HIV Escape and T-Cell Control of HIV
HIV Escape and T-Cell Control of HIV
George M. Shaw,
University of Pennsylvania, USA
HIV-1 Sequences in Acute and Early Infection Reveal the Genetic Identity, Biological Phenotype, and Precise Evolutionary Pathways of Transmitted/Founder Viruses and their Progeny
HIV-1 Sequences in Acute and Early Infection Reveal the Genetic Identity, Biological Phenotype, and Precise Evolutionary Pathways of Transmitted/Founder Viruses and their Progeny
11:00—12:30
Hands On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
14:30—15:30
Workshop 1A: New Therapeutics
*
Dana H. Gabuzda,
Dana Farber Cancer Institute, USA
Daria J. Hazuda,
Merck Research Laboratories, USA
Integrase Inhibitors
Integrase Inhibitors
Mike Westby,
Pfizer Global Research and Development, UK
CCR5 Antagonists as HIV Entry Inhibitors
CCR5 Antagonists as HIV Entry Inhibitors
Navid Madani,
Dana Farber Cancer Institute, USA
New Entry Inhibitors: Interaction of Small-Molecule CD4 Mimics with a Highly Conserved Pocket on the HIV gp120 Envelope Glycoprotein
New Entry Inhibitors: Interaction of Small-Molecule CD4 Mimics with a Highly Conserved Pocket on the HIV gp120 Envelope Glycoprotein
15:30—16:30
Workshop 1B: Th17 Cells
*
Robert F. Siliciano,
Johns Hopkins University School of Medicine, USA
Aimee El Hed,
New York University School of Medicine, USA
Human Th17 Cells are Highly Susceptible to CCR5-Tropic HIV Infection and are Preferentially Depleted in Infected Individuals
Human Th17 Cells are Highly Susceptible to CCR5-Tropic HIV Infection and are Preferentially Depleted in Infected Individuals
Nicolas Manel,
Institut Curie, France
The Differentiation of Human Th17 Cells Requires TGF-beta and Induction of the Nuclear Receptor RORgammat and this Renders T Cells more Susceptible to HIV-1 Infection
The Differentiation of Human Th17 Cells Requires TGF-beta and Induction of the Nuclear Receptor RORgammat and this Renders T Cells more Susceptible to HIV-1 Infection
Petronela Ancuta,
Centre de Recherche de l'Universite de Montreal, Canada
HIV Replicates in CCR6+IFN-gamma+IL-17+ but Not CCR6negIFN-gamma+IL-10+ Primary CD4+ T-Cell Subsets
HIV Replicates in CCR6+IFN-gamma+IL-17+ but Not CCR6negIFN-gamma+IL-10+ Primary CD4+ T-Cell Subsets
Anna Aldovini,
Boston Children's Hospital and Harvard Medical School, USA
Tat-Induced FOXO3a is a Key Mediator of Apoptosis in HIV-1-Infected Human CD4+ T-Lymphocytes
Tat-Induced FOXO3a is a Key Mediator of Apoptosis in HIV-1-Infected Human CD4+ T-Lymphocytes
17:00—19:15
How to Improve Vaccine Efficacy? Adjuvants, Route of Administration...
Bali Pulendran,
Stanford University School of Medicine, USA
Modulating Vaccine Responses with Innate Immunity
Modulating Vaccine Responses with Innate Immunity
Susan W. Barnett,
Bill & Melinda Gates Foundation, USA
HIV Antigen Discovery and Novel Vaccine Deliveries Using Recombinant Alphavirus Replicon Particles and Adjuvanted Proteins
HIV Antigen Discovery and Novel Vaccine Deliveries Using Recombinant Alphavirus Replicon Particles and Adjuvanted Proteins
Christopher J. Miller,
University of California, Davis, USA
A T Cell Vaccine that Elicits Mucosal CD8+ Effector Cells in a Setting of Minimal Immune Activation Can Protect Rhesus Monkeys from Vaginal SIV Challenge
A T Cell Vaccine that Elicits Mucosal CD8+ Effector Cells in a Setting of Minimal Immune Activation Can Protect Rhesus Monkeys from Vaginal SIV Challenge
Barbara K. Felber,
NCI, National Institutes of Health, USA
Short Talk: Electroporation of Optimized DNA Vaccines Leads to Greatly Enhanced Systemic and Mucosal Immune Responses and Control of Pathogenic SIVmac251 Challenge: Antibodies Contribute to Virus Containment
Short Talk: Electroporation of Optimized DNA Vaccines Leads to Greatly Enhanced Systemic and Mucosal Immune Responses and Control of Pathogenic SIVmac251 Challenge: Antibodies Contribute to Virus Containment
Johannes Fabian Scheid,
Massachusetts General Hospital - Harvard, USA
Short Talk: Search for Broadly Neutralizing Antibodies against HIV using a Single Cell Approach
Short Talk: Search for Broadly Neutralizing Antibodies against HIV using a Single Cell Approach
17:00—19:00
Models of HIV Immunobiology
*
Frank Kirchhoff,
University of Ulm, Germany
Guido Silvestri,
Emory University School of Medicine, USA
SIV Infection of African Monkeys: A New Paradigm for AIDS Pathogenesis and Vaccines
SIV Infection of African Monkeys: A New Paradigm for AIDS Pathogenesis and Vaccines
Cecilia Cheng-Mayer,
Aaron Diamond AIDS Research Center, USA
Coreceptor switching in the SHIV/macaque model
Coreceptor switching in the SHIV/macaque model
Sarah L. Rowland-Jones,
Oxford University, UK
Long-term non-progression with HIV infection: lessons from HIV-2
Long-term non-progression with HIV infection: lessons from HIV-2
08:00—11:00
How to Generate Vaccine Efficacy against HIV? T Cell-Based and B-Cell Based Vaccines
*
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois, Switzerland
Barton F. Haynes,
Duke University Medical Center, USA
What Does a Successful HIV-1 Vaccine Need To Do? Clues From Acute HIV-1 Infection
What Does a Successful HIV-1 Vaccine Need To Do? Clues From Acute HIV-1 Infection
Dan H. Barouch,
Beth Israel Deaconess Medical Center, USA
Novel Adenovirus Vector-Based Vaccines for HIV-1
Novel Adenovirus Vector-Based Vaccines for HIV-1
Dennis R. Burton,
The Scripps Research Institute, USA
Mechanisms of Antibody Protection Against HIV
Mechanisms of Antibody Protection Against HIV
Amitinder Kaur,
New England Regional Primate Research Center, USA
Short Talk: Protective Efficacy of a Replication-Defective Herpes Simplex Virus-based AIDS Vaccine Against High Dose Intra-Rectal SIVmac239 Challenge
Short Talk: Protective Efficacy of a Replication-Defective Herpes Simplex Virus-based AIDS Vaccine Against High Dose Intra-Rectal SIVmac239 Challenge
08:00—11:00
New Insights in HIV Replication
*
Michael H. Malim,
King's College London, UK
Frank Kirchhoff,
University of Ulm, Germany
Role of Nef in vivo and in vitro
Role of Nef in vivo and in vitro
Christopher Aiken,
Vanderbilt University School of Medicine, USA
Cyclophilin A and HIV-1 Uncoating
Cyclophilin A and HIV-1 Uncoating
Nathaniel R. Landau,
New York University School of Medicine, USA
Vpr and DNA Damage
Vpr and DNA Damage
John C. Guatelli,
University of California, San Diego, USA
Short Talk: Vpu Antagonizes BST-2-Mediated Restriction of HIV-1 Release via b-TrCP and Endo-Lysosomal Trafficking
Short Talk: Vpu Antagonizes BST-2-Mediated Restriction of HIV-1 Release via b-TrCP and Endo-Lysosomal Trafficking
Andres Finzi,
CRCHUM, Université de Montréal, Canada
Short Talk: A Layered Structure in the HIV-1 gp120 Inner Domain Regulates gp41 Interaction and Facilitates Transitions into the CD4-Bound Conformation
Short Talk: A Layered Structure in the HIV-1 gp120 Inner Domain Regulates gp41 Interaction and Facilitates Transitions into the CD4-Bound Conformation
14:30—16:30
Workshop 1: Which Immune Correlates of Protection against HIV? How to Measure T Cell and B Cell Correlates? Supported in part by the French Agency for AIDS Research (ANRS)
*
Richard A. Koup,
NIAID, National Institutes of Health, USA
Asier Sáez-Cirión,
Institut Pasteur, France
The Strong HIV Suppressive Capacity of CD8+ T Cells from HIV Controllers is Associated with Gag-Specific CD8+ T Cell Responses
The Strong HIV Suppressive Capacity of CD8+ T Cells from HIV Controllers is Associated with Gag-Specific CD8+ T Cell Responses
Adam R. Hersperger,
Thomas Jefferson University, USA
HIV-Specific CD8 T Cells from Elite Controllers Rapidly Upregulate Perforin
HIV-Specific CD8 T Cells from Elite Controllers Rapidly Upregulate Perforin
Meritxell Genescà,
Health Sciences Research Institute Germans Trias i Pujol Foundation, Spain
For the CD8+ T Cells to be Effective in the Context of a Live-Attenuated Vaccine Differential Immune Activation is Critical
For the CD8+ T Cells to be Effective in the Context of a Live-Attenuated Vaccine Differential Immune Activation is Critical
Jorge Ramos de Almeida,
NIAID, National Institutes of Health, USA
Antigen Sensitivity is a Major Determinant of CD8+ T Cell Efficacy in HIV-1 Infection
Antigen Sensitivity is a Major Determinant of CD8+ T Cell Efficacy in HIV-1 Infection
Leonidas Stamatatos,
Fred Hutchinson Cancer Research Center, USA
Broad Neutralizing Antibody Responses during HIV-1 Infection: Prevalence and Epitope Specificities
Broad Neutralizing Antibody Responses during HIV-1 Infection: Prevalence and Epitope Specificities
Nicole A. Doria-Rose,
NIAID, National Institutes of Health, USA
Breadth of Neutralizing Antibodies in HIV+ Serum: Clustering Analysis and Association with Clinical Variables
Breadth of Neutralizing Antibodies in HIV+ Serum: Clustering Analysis and Association with Clinical Variables
Ann J. Hessell,
Oregon Health & Science University, USA
Complete Protection Provided by Antibodies 2F5 and 4E10 Against Mucosal SHIV BaL Challenge
Complete Protection Provided by Antibodies 2F5 and 4E10 Against Mucosal SHIV BaL Challenge
Vincent Holl,
Institute of Virology, France
Identification of HIV-Specific IgG that Inhibit Infection of Mucosal HIV Target Cells
Identification of HIV-Specific IgG that Inhibit Infection of Mucosal HIV Target Cells
13:30—16:30
NIAID Workshop on Identification and Validation of New Cellular Co-Factors in HIV Replication. Organized by Roger Miller and Opendra Sharma, DAIDS, NIAID. Moderators: Roger Ptak and Warner Greene.
The objective of the workshop will be to discuss the current status of the field; determine the best approach for validating the mechanism of action of host molecules in primary cells; and, promote development of assays which recreate the activity of a cellular co-factor, or a cellular restriction, with the goal of producing a high throughput screening assay for testing chemical compound libraries.
Carl W. Dieffenbach,
NIAID, National Institutes of Health, USA
Workshop Objectives
Workshop Objectives
*
Roger Ptak,
Southern Research Institute, USA
Cataloging the HIV-Human Protein Interaction Network
Cataloging the HIV-Human Protein Interaction Network
John A. T. Young,
F.Hoffmann-La Roche Ltd, Switzerland
Genome-Wide Screeing of HIV-Host Interactions
Genome-Wide Screeing of HIV-Host Interactions
*
Warner Craig Greene,
Gladstone Institute of Virology and Immunology, USA
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening
Dana H. Gabuzda,
Dana Farber Cancer Institute, USA
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening
Tariq M. Rana,
University of California, San Diego, USA
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening
Small Molecule Inhibitors of the Vif-APOBEC3G Interaction of HIV-1 Identified by High Throughput Screening
Warner Craig Greene,
Gladstone Institute of Virology and Immunology, USA
Wrap-Up and Future Directions
Wrap-Up and Future Directions
17:00—19:00
HIV at the Mucosa: Portal of Entry and Front-Line Defense (Joint)
*
Daniel C. Douek,
NIAID, National Institutes of Health, USA
Ashley T. Haase,
University of Minnesota, USA
Keynote Address: Quest for Design Principles for an Effective HIV Vaccine/Microbicide in Studies of SIV Pathogenesis
Keynote Address: Quest for Design Principles for an Effective HIV Vaccine/Microbicide in Studies of SIV Pathogenesis
Alison Simmons,
Weatherall Institute of Molecular Medicine, UK
Dendritic Cell Factors Required for HIV-1 Infection
Dendritic Cell Factors Required for HIV-1 Infection
Ronald S. Veazey,
Tulane National Primate Research Center, USA
_7 Integrin Expression on CD4+ T Cells as a Surrogate Marker for Tracking Intestinal CD4+ T Cell Loss in SIV Infection
_7 Integrin Expression on CD4+ T Cells as a Surrogate Marker for Tracking Intestinal CD4+ T Cell Loss in SIV Infection
Satya Dandekar,
University of California, Davis, USA
Short Talk: Mechanisms of Impaired Gut Mucosal Defenses during HIV and SIV Infections
Short Talk: Mechanisms of Impaired Gut Mucosal Defenses during HIV and SIV Infections
08:00—11:15
HIV-HSV-2 Interactions and Lessons from Clinical Trials of Preventative Vaccines
Lawrence Corey,
Fred Hutchinson Cancer Research Center, USA
Mechanism behind the HSV-2-HIV Interaction: Subclinical Persistence of HIV Receptor Positive Cells
Mechanism behind the HSV-2-HIV Interaction: Subclinical Persistence of HIV Receptor Positive Cells
*
Scott M. Hammer,
Columbia University, USA
Challenges in Preventative Vaccine Development
Challenges in Preventative Vaccine Development
Susan P. Buchbinder,
San Francisco Department of Public Health, USA
Clinical Endpoints in the Step Study
Clinical Endpoints in the Step Study
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Lessons from the HIV-Ad5 Vaccine Phase II Clinical Trial
Lessons from the HIV-Ad5 Vaccine Phase II Clinical Trial
Merlin L. Robb,
Walter Reed Army Institute of Research, USA
Lessons from the Thai ALVAC-gp120 HIV Vaccine Efficacy Trial: A Community Based Study
Lessons from the Thai ALVAC-gp120 HIV Vaccine Efficacy Trial: A Community Based Study
08:00—11:00
Innate Antiviral Immunity
*
Christopher Aiken,
Vanderbilt University School of Medicine, USA
Michael H. Malim,
King's College London, UK
APOBEC3 Proteins and Intrinsic Resistance to HIV-1 Infection
APOBEC3 Proteins and Intrinsic Resistance to HIV-1 Infection
Warner Craig Greene,
Gladstone Institute of Virology and Immunology, USA
The Role of APOBEC3 Enzymes in Counteracting “Retro-Threats”, Both Foreign and Domestic
The Role of APOBEC3 Enzymes in Counteracting “Retro-Threats”, Both Foreign and Domestic
Greg J. Towers,
University College London, UK
Inhibition of Retroviral Infection by TRIMCyp and Tetherin Reveals a Delicate Balance between Viral Countermeasures and Host Restriction
Inhibition of Retroviral Infection by TRIMCyp and Tetherin Reveals a Delicate Balance between Viral Countermeasures and Host Restriction
Didier Trono,
Ecole Polytechnique Fédérale de Lausanne, Switzerland
Epigenetic Control of Retroelements
Epigenetic Control of Retroelements
14:30—16:30
Workshop 2: Clinical Trials Design. Supported in part by the French Agency for AIDS Research (ANRS)
*
Scott M. Hammer,
Columbia University, USA
Dean Follmann,
National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
Crossover Designs for HIV Prevention Trials
Crossover Designs for HIV Prevention Trials
Peter Gilbert,
Fred Hutchinson Cancer Research Center, USA
Leveraging Baseline Characteristics to Improve Prevention Trials
Leveraging Baseline Characteristics to Improve Prevention Trials
Frances Priddy,
International AIDS Vaccine Initiative, USA
HIV Vaccines and PrEP
HIV Vaccines and PrEP
Heather B. Jaspan,
University of Cape Town, South Africa
HIV Vaccine Trials in Adolescents
HIV Vaccine Trials in Adolescents
17:00—19:00
Prevention of AIDS: What can we Learn from Therapeutic Vaccines
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC, France
Lessons for Therapeutic Vaccines against HIV for Immune Correlates of Protection against HIV
Lessons for Therapeutic Vaccines against HIV for Immune Correlates of Protection against HIV
*
Rafick Sekaly,
Case Western Reserve University, USA
Improving and Modeling of Therapeutic Autologous Dendritic Cell Vaccine for HIV-1 Infection
Improving and Modeling of Therapeutic Autologous Dendritic Cell Vaccine for HIV-1 Infection
Stephen J. Kent,
University of Melbourne, Australia
Short Talk: Reduced Viremia and Delayed Disease Progression Following Immunotherapy of SIV with Antigen Pulsed Blood
Short Talk: Reduced Viremia and Delayed Disease Progression Following Immunotherapy of SIV with Antigen Pulsed Blood
Glenda E. Gray,
South African Medical Research Council, South Africa
HIV Vaccine Trials in South Africa: Looking Forward from Phambili
HIV Vaccine Trials in South Africa: Looking Forward from Phambili
17:00—19:15
Virus Spread
*
Alison Simmons,
Weatherall Institute of Molecular Medicine, UK
Olivier Schwartz,
Institut Pasteur, France
Mechanisms of Direct HIV Lymphocyte-to-Lymphocyte Transfer: Role of “Polysynapses”
Mechanisms of Direct HIV Lymphocyte-to-Lymphocyte Transfer: Role of “Polysynapses”
Thomas J. Hope,
Northwestern University, USA
Interaction of HIV with Cells within Intact Mucosal Tissue
Interaction of HIV with Cells within Intact Mucosal Tissue
Vincent Piguet,
Cardiff University, UK
Mechanisms of DC-T Cell HIV-1 Transmission via an Infectious Synapse
Mechanisms of DC-T Cell HIV-1 Transmission via an Infectious Synapse
Walther Mothes,
Yale University School of Medicine, USA
Short Talk: Retroviral Assembly is Directed Towards Sites of Cell-Cell Contact
Short Talk: Retroviral Assembly is Directed Towards Sites of Cell-Cell Contact
Sriram Subramaniam,
University of British Columbia, Canada
Short Talk: 3D Architecture of the Virological Synapse and Structural Mechanisms of HIV Entry
Short Talk: 3D Architecture of the Virological Synapse and Structural Mechanisms of HIV Entry
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
|
|
|
GenVec, Inc. |
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
